Local review candidate. Draft legal research awaiting editorial review.
With JavaScript enabled, choose any of the 50 states or DC and keep saved regions and read marks in this browser.
Regional source notebook
Draft research for New Jersey, New York, Massachusetts, Ohio and New Hampshire. Sources may describe earlier changes. This is not a complete list of current law or pending proposals.
Later amendments, court orders and enforcement practice have not been comprehensively checked.
New Jersey · Drug checking Draft research
Harm reduction supplies excluded from paraphernalia definition
Draft status: Operative in cited text
New Jersey’s 2023 act excludes harm reduction supplies from its drug-paraphernalia definition. The definition includes test strips and equipment for identifying or analyzing substances. The act was approved January 8, 2024 and took effect immediately.
Scope and exceptions: The supplies must fit the statutory harm-reduction definition. This is not a general exemption for possessing controlled substances. Some listed supplies have conditions tied to an authorized service provider. Current codification and later amendments still need editorial reconciliation.
From January 16, 2025, Public Health Law §3309-b includes testing for xylazine or other substances alongside fentanyl and its analogs. It authorizes dispensing by health care professionals and pharmacists and says a license is not required to distribute these supplies.
Scope and exceptions: The page displays both the earlier and later definitions; this summary uses the later one. A supply-distribution provision does not itself establish blanket immunity for controlled-substance possession or authorize every drug-checking service.
Protections for defined drug-testing service roles
Draft status: Operative in cited text
Chapter 94C §34A½ permits people acting in good faith within specified harm-reduction service roles to provide drug testing for someone’s personal-use substance. It protects those providers and on-site clients from specified charges. The 2024 act added this section.
Scope and exceptions: The exact effective date remains unverified. Client protection is limited to the testing premises and §§32I, 34 and 40. The provider liability protection excludes gross negligence and willful or wanton misconduct. Good faith, role and exclusive personal-use conditions matter.
Approved testing strips and reagent kits cover specified compounds
Draft status: Operative in cited text
Effective November 1, 2025, Rule 4729-8-02 approves strips and reagent kits for detecting fentanyl-related compounds, xylazine, medetomidine, nitazenes and benzodiazepine-related compounds. Ohio’s statute provides a use-or-possession exception for fentanyl strips and instruments approved by the pharmacy board.
Scope and exceptions: Approval depends on the instrument and compounds. Section 4729.261(B) bars board approval to the extent an instrument is intended to measure mixture purity. Additional board resolutions and the statutes’ cross-references need review before broader claims about sales, instruments or possession of substances.
Fentanyl and xylazine testing exception has conditions
Draft status: Operative in cited text
RSA 318-B:1(X-b) excludes fentanyl and xylazine strips and other materials for testing those substances or their analogs from the paraphernalia definition. The exception has an accompanying-evidence condition involving manufacturing, possession with intent to sell or compounding charges.
Scope and exceptions: The exception’s amendment and effective date remain unverified. It does not establish a general exemption for all drug-checking equipment or substance possession. Read the accompanying-evidence condition in full before relying on this summary.
A808-C would establish a health-department drug-checking program with surveillance duties and specified participant protections. The official page lists it in Assembly Ways and Means, with referral on January 7, 2026.
Scope and exceptions: This bill is not operative law. The C amendment uses different commencement language from earlier versions. Enactment, final text and commencement must be checked before any public guidance changes.
S.1057 would exclude fentanyl strips and equipment used solely to detect fentanyl or its analogs from the testing-equipment portion of the paraphernalia definition. The Senate passed it to be engrossed; it was referred to House Ways and Means on September 22, 2025.
Scope and exceptions: Senate passage is not enactment. The official page still lists House Ways and Means. The proposed wording is fentanyl-specific and should not be generalized to all drug checking.